Concepedia
Statistics
Publications
21
Citations
1.5K
H-Index
19
Active since
1997
Affiliations
Pharmalog (Germany)(Current)
Neovii Biotech (Germany)
Ludwig-Maximilians-Universität München
Charité - Universitätsmedizin Berlin
University of Regensburg
Michael Jäger is an author at Pharmalog (Germany) specializing in life sciences, immunology, and oncology.
Publications per year
1997–2022
Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study
Alexander Burges, Pauline Wimberger, Carolin Kümper et al. · Clinical Cancer Research · 2007 · 257 citations
Medicine, Oncology, Pharmacology +17
Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast Cancer
Philipp Kiewe, Stephan Hasmüller, Steffen Kahlert et al. · Clinical Cancer Research · 2006 · 197 citations · Full text
Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3)
Michael Jäger, A. Schoberth, Peter Ruf et al. · Cancer Research · 2011 · 118 citations · Full text
Life Sciences, Immunology, Oncology +17
Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
Peter Ruf, Olivier Gires, Michael Jäger et al. · British Journal of Cancer · 2007 · 100 citations · Full text
The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2
Michael Jäger, A. Schoberth, Peter Ruf et al. · Cancer Research · 2009 · 93 citations · Full text
Medicine, Immunology, Oncology +17
1–5 of 21